EMA Authorised: Tepezza (teprotumumab) — Amgen Europe B.V.

View source ↗

Summary

The European Medicines Agency authorised Tepezza (teprotumumab) for Graves' ophthalmopathy, with Amgen Europe B.V. as the marketing authorization holder. This m…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graves Ophthalmopathy

Drugs mentioned

• TEPEZZA (teprotumumab)

Snippet

Status: Authorised. Therapeutic area: Graves Ophthalmopathy. MAH: Amgen Europe B.V.. Decision date: 25/03/2026